Cargando…
Is critical care ready for an economic surrogate endpoint?
Intensive care is expensive, and thus a body of research has focused on strategies to reduce its costs. However, efforts to reduce the total cost of intensive care have met with limited success, partly because of the challenges of calculating how much a day in the ICU actually costs. We discuss thes...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464123/ https://www.ncbi.nlm.nih.gov/pubmed/26067467 http://dx.doi.org/10.1186/s13054-015-0947-0 |
_version_ | 1782375895375282176 |
---|---|
author | Wilcox, M Elizabeth Rubenfeld, Gordon D |
author_facet | Wilcox, M Elizabeth Rubenfeld, Gordon D |
author_sort | Wilcox, M Elizabeth |
collection | PubMed |
description | Intensive care is expensive, and thus a body of research has focused on strategies to reduce its costs. However, efforts to reduce the total cost of intensive care have met with limited success, partly because of the challenges of calculating how much a day in the ICU actually costs. We discuss these challenges and introduce the concept of total cost savings as an outcome of critical care trials, assuming statistically negative effects on mortality and quality of life. |
format | Online Article Text |
id | pubmed-4464123 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44641232015-06-14 Is critical care ready for an economic surrogate endpoint? Wilcox, M Elizabeth Rubenfeld, Gordon D Crit Care Commentary Intensive care is expensive, and thus a body of research has focused on strategies to reduce its costs. However, efforts to reduce the total cost of intensive care have met with limited success, partly because of the challenges of calculating how much a day in the ICU actually costs. We discuss these challenges and introduce the concept of total cost savings as an outcome of critical care trials, assuming statistically negative effects on mortality and quality of life. BioMed Central 2015-06-11 2015 /pmc/articles/PMC4464123/ /pubmed/26067467 http://dx.doi.org/10.1186/s13054-015-0947-0 Text en © Wilcox and Rubenfeld. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Commentary Wilcox, M Elizabeth Rubenfeld, Gordon D Is critical care ready for an economic surrogate endpoint? |
title | Is critical care ready for an economic surrogate endpoint? |
title_full | Is critical care ready for an economic surrogate endpoint? |
title_fullStr | Is critical care ready for an economic surrogate endpoint? |
title_full_unstemmed | Is critical care ready for an economic surrogate endpoint? |
title_short | Is critical care ready for an economic surrogate endpoint? |
title_sort | is critical care ready for an economic surrogate endpoint? |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464123/ https://www.ncbi.nlm.nih.gov/pubmed/26067467 http://dx.doi.org/10.1186/s13054-015-0947-0 |
work_keys_str_mv | AT wilcoxmelizabeth iscriticalcarereadyforaneconomicsurrogateendpoint AT rubenfeldgordond iscriticalcarereadyforaneconomicsurrogateendpoint |